2020 American Transplant Congress
Multicenter Evaluation of Cytomegalovirus Infection Following Intestinal and Multivisceral Transplantation
1Duke University Hospital, Chapel Hill, NC, 2Henry Ford Hospital, Detroit, MI
*Purpose: Evaluate factors related to incidence and outcomes of cytomegalovirus (CMV) infection after isolated intestinal transplantation (IT) and multivisceral transplantation (MVT).*Methods: Retrospective evaluation of 32…2020 American Transplant Congress
Conversion to Sirolimus to Prevent Recurrent Cytomegalovirus Infection/Disease: A Prospective and Randomized Trial
Hospital do Rim - UNIFESP, São Paulo, Brazil
*Purpose: Recurrent cytomegalovirus (CMV) infection occurs in 30-35% of kidney transplant recipients after completion of treatment and/or preemptive therapy. There is no consensus on the…2020 American Transplant Congress
Influence of HLA Compatibility on Cytomegalovirus Infection Post-Kidney Transplantation
*Purpose: Cytomegalovirus (CMV) infection after kidney transplantation is associated with a high morbidity and higher risk of graft loss. A latent Human CMV infection can…2020 American Transplant Congress
Identification of Cell Types That Harbor Cytomegalovirus DNA in Acutely and Latently Infected Mice Spleen
*Purpose: Cytomegalovirus (CMV) is a ubiquitous β‐herpesvirus that infects majority of humans. Primary CMV infection may be asymptomatic or manifests as a self‐limited febrile illness…2020 American Transplant Congress
Evaluation of the Safety and Efficacy of Valganciclovir to Prevent Cytomegalovirus Infection in Pediatric Solid Organ Transplant Recipients Utilizing Two Dosing Regimens
Pharmacy, Ann and Robert H. Lurie Children's Hospital, Chicago, IL
*Purpose: Valganciclovir (VGCV) is FDA-approved for CMV prophylaxis in children aged one month to sixteen years old using the Pescovitz algorithm (7 x body surface…2020 American Transplant Congress
The Value of Pharmacist-Driven Valganciclovir Dosing in Kidney Transplant Recipients in Reducing CMV Infection: A Single Center Experience
*Purpose: Cytomegalovirus (CMV) is a common viral infection after kidney transplant (KT) despite prophylaxis with valganciclovir (VGCV). VGCV is renally dosed and can be a…2020 American Transplant Congress
CMV, EBV and BKV Viremia Rate Varied Depending on the Timing of Conversion to Belatacept (BLT)- from Calcineurin Inhibitor (CNI)-Based Immunosuppression and HLA-Sensitization (HS) Status in Kidney Transplant Patients (KTx Pts)
Cedars-Sinai Medical Center, Los Angeles, CA
*Purpose: Viral infections (VI) represent significant morbidity and mortality factors for KTx Pts. We previously showed more VI in BLT-treated Pts compared with CNI Pts…2020 American Transplant Congress
Reduced Dose Valganciclovir is Effective for CMV Prevention without Excess Breakthrough or Resistance in Kidney Transplantation
*Purpose: Reduced dose valganciclovir (VGC) (450 mg daily) may be a useful alternative to full dose VGC for cytomegalovirus (CMV) prophylaxis due to drug cost…2020 American Transplant Congress
Efficacy Of CMV Prophylaxis In Liver Transplant Recipients
Intermountain Medical Center, Murray, UT
*Purpose: Human cytomegalovirus (CMV) is a ubiquitous beta herpesvirus present in the human population at rates between 30% and 90%. It can be transmitted via…2020 American Transplant Congress
Conversion to Belatacept (BLT)- from Calcineurin Inhibitor (CNI)-Based Immunosuppression During the First Year Post-Transplant (<1yr Tx) Increases Risk for CMV Infection Through Inhibition of Anti-CMV Humoral Immunity
Cedars-Sinai Medical Center, Los Angeles, CA
*Purpose: We have shown a higer CMV infection rate in kidney Tx patients (KTx Pts) who were converted to BLT 1yr post-Tx. Viral infections are…
- « Previous Page
- 1
- …
- 7
- 8
- 9
- 10
- 11
- …
- 33
- Next Page »